Status:

UNKNOWN

Meropenem and Ciprofloxacin Dosing in Septic Shock

Lead Sponsor:

Rigshospitalet, Denmark

Collaborating Sponsors:

The University of Queensland

Conditions:

Septic Shock

Eligibility:

All Genders

18-90 years

Brief Summary

Patients with septic shock may have altered volume of distribution and metabolism of antibiotics which are crucial medications for treating infections. The aim of the study is to investigate the blood...

Detailed Description

Sepsis may induce changes in renal function, increased capillary leakage and frequently blood-flow stasis in the peripheral tissues leading to an increase in the water space and diffusion distances. S...

Eligibility Criteria

Inclusion

  • Age \>18 years and \<90 years
  • Clinical indication for therapy of one of the study antibiotics Meropenem or Ciprofloxacin in patients diagnosed at or during admission to ICU with septic shock
  • Sepsis will be defined as:
  • Clinical suspicion of infection and/or Positive culture results
  • Systemic inflammatory response syndrome (SIRS) as defined by 2 or more of the following:
  • Core temperature \< 36o C or \> 38o C
  • Tachycardia as defined by a heart rate \> 90 beats per minute
  • Tachypnoea as defined by a respiratory rate greater than 20 breaths per minute OR a PaCO2 less than 32 mmHg during spontaneous ventilation OR the requirement for mechanical ventilation.
  • A white blood cell count \> 12 X 109 / L OR \< 4 X 109 / L OR greater than 10 % immature (band) forms.
  • Septic shock will be defined as:
  • Sepsis with persistent hypotension, systolic blood pressure \< 90 mmHg or mean arterial pressure \< 65 despite adequate fluid resuscitation
  • Requirement of inotropic support.
  • Normal renal function as defined by:
  • Serum creatinine \<170 mmol/L

Exclusion

  • Pre-existing renal impairment as defined by:
  • Serum creatinine above normal limits ( defined as \>500mmol/L)
  • Need for renal replacement therapy
  • History of allergy to study antibiotic
  • Pregnancy

Key Trial Info

Start Date :

November 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 1 2016

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT02240277

Start Date

November 1 2014

End Date

March 1 2016

Last Update

September 15 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rigshospitalet

Copenhagen, Denmark, 2100

Meropenem and Ciprofloxacin Dosing in Septic Shock | DecenTrialz